Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453689 | 0.93 | HTR2A (0.34) | HTR2AKDM4ELMNATP53CHRM2 | |
| SCHEMBL1452984 | 0.89 | HTR2A (0.39) | HTR2AKDM4ELMNATP53CHRM2 | |
| SCHEMBL1452810 | 0.82 | HTR2A (0.35) | HTR2AKDM4ELMNATP53CHRM2 | |
| SCHEMBL1452993 | 0.81 | — | — | |
| SCHEMBL1452870 | 0.78 | HTR2A (0.42) | HTR2AKDM4ELMNATP53CHRM2 | |
| Hydrochloric Acid SCHEMBL27932951 | 0.77 | CDC25A (0.31) | HTR2ACDC25ACDC25B | |
| Fluoride Ion SCHEMBL27932962 | 0.77 | CDC25A (0.31) | HTR2ACDC25ACDC25B | |
| Iodide SCHEMBL27948719 | 0.77 | CDC25A (0.31) | HTR2ACDC25ACDC25B | |
| Bromide SCHEMBL27933105 | 0.77 | HTR2A (0.34) | HTR2AKDM4ELMNATP53CHRM2 | |
| SCHEMBL5160641 | 0.76 | CDC25A (0.32) | CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1971621-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007070045-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1017729-B1 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY AMORPHOUS ALPHA-OLEFIN POLYMERS, COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF BRIDGED LIGAND | BASELL POLYOLEFINE GMBH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-6844288-B2 | Process for the preparation of ligands for metallogene catalysts | BASELL POLYOLEFINE GMBH (DE) | 2005-01-18 | — | — | US | disclosed |
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | EQUISTAR CHEMICALS, LP | 2003-08-21 | — | — | US | disclosed |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | RESCONI LUIGI (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6423796-B1 | COORDINATION CATALYST | BASEL TECHNOLOGY COMPANY BV (NL) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158356-A1 | Process for the preparation of substantially amorphous alpha-olefin polymers and compositions containing them and process for the preparation of bridged ligand | MACF1, SDC1, SDC2 | HTR2A 4160/4885KDM4E 3924/4885LMNA 1502/4885 |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | HTR2A 4085/4885KDM4E 3402/4885LMNA 1155/4885 |
| US-20020169260-A1 | Process for the preparation of ligands for metallocene catalysts | SDC1, SDC2, SDC4 | HTR2A 3843/4885KDM4E 4267/4885LMNA 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.